Skip to main content

Advertisement

Table 1 Clinical and biochemical characteristics of the study participants

From: Role of disturbed fatty acids metabolism in the pathophysiology of diabetic erectile dysfunction

Characteristics Patients with VED (n = 72) Patients w/o VED (n = 78) Controls (n = 88)
Clinical profile
 Age (years) 57.7 ± 5.1 58.8 ± 4.8 55.9 ± 7.0
 BMI (kg/m2) 26.75 ± 4.8 27.43 ± 3.2 25.15 ± 3.8
 Duration of T2D (years) 10.95 ± 7.1 8.25 ± 5.4 __
 Duration of ED (years) 3.30 ± 2.9 __ __
Biochemical profile
 Fasting Glucose (mmoL/L) 9.87 ± 3.7** 8.36 ± 2.1** 5.27 ± 0.9
 HbA1c (mmoL/mol) 95** 77** 38
 Insulin (μIU/mL) 5.62 ± 3.6* 4.93 ± 2.7* 3.56 ± 2.4
 HOMA IR 2.39 ± 1.7** 1.83 ± 1.1** 0.83 ± 0.4
 NO (ng/L) 1.43 ± 1.18*** 3.09 ± 1.85 3.30 ± 2.92
Serum lipid profile (mmoL/L)
 Total cholesterol 4.54 ± 0.8* 4.43 ± 0.8* 4.06 ± 0.9
 Triglycerides 1.60 ± 0.9 1.77 ± 0.7* 1.37 ± 0.5
 LDLc 2.70 ± 0.94* 2.68 ± 0.9* 2.27 ± 1,02
 HDLc 1.03 ± 0.3 0.94 ± 0.4 1.1 ± 0.4
Serum Hepatic profile (IU/L)
 AST 23.19 ± 7.5 21.5 ± 8.4* 24.28 ± 8.9
 ALT 20.26 ± 11.6* 21.36 ± 10.4* 25.01 ± 12.3
  1. Values are given as mean ± standard error
  2. BMI Body mass index, HbA1c glycated hemoglobin, HOMA IR homeostatic index of insulin resistance, LDLc low density lipoprotein-cholesterol, HDLc High density lipoprotein-cholesterol, AST aspartate aminotransferase, ALT alanine aminotransférase, w/o without
  3. *P < 0.05 and **P < 0.001 compared to controls